After nearly two years of critical shortages, ADHD medication supply is finally stabilizing. The DEA has increased manufacturing quotas and generic availability is expanding.
Current Status
- Adderall (amphetamine salts): Widely available for the first time since 2023
- Vyvanse: Generic lisdexamfetamine now available from 3 manufacturers, prices down 80%
- Concerta: Supply normalized, but some generic versions remain limited
- Ritalin: Fully available in all formulations
What Caused the Shortage
A perfect storm: post-pandemic ADHD diagnosis surge (up 35%), DEA production quotas not keeping pace, and raw material supply chain disruptions. Telehealth made diagnosis more accessible, but the system couldn't keep up with prescriptions.
For Patients
If you've been struggling to fill prescriptions, call your pharmacy about current availability. Generic Vyvanse at $30-$50/month (vs $400+ for brand) is a game-changer. Talk to your doctor about switching formulations if your preferred medication remains limited.
